BioCentury | Jan 17, 2020
Company News

Jan. 17 Company Quick Takes: FDA expands label of Novo’s Ozempic; plus Intercept, Durect, Coherus-Innovent, CoImmune-Formula and Momenta

...been determined. Coherus takes territorial rights to Innovent’s Avastin biosimilar Innovent Biologics Inc. (HKSE:1801) granted Coherus BioSciences...
...subcutaneous semaglutide (Informal) Ocaliva, obeticholic acid (DSP-1747, 6ecdca, int-747, oca) Novo Nordisk A/S Intercept Pharmaceuticals Inc. Durect Corp. Innovent Biologics Inc. Coherus BioSciences...
BioCentury | Jan 7, 2020
Company News

Management tracks: New director for CMS’s CMMI, plus FibroGen, Turning Point, Akcea, Antengene, Biocon and more

...as its first chief commercial officer. Hassard was SVP of marketing and market access at Coherus BioSciences...
BioCentury | Dec 7, 2019
Product Development

U.S. biosimilars glass--half full or half empty?

...pegfilgrastim launched in the U.S. in July 2018, it has been joined by Udenyca from Coherus Biosciences...
...value certainty in supply and patient and provider services.” The launch of Ziextenzo, the Sandoz biosimilar pegfilgrastim...
...CenTNF (Former), Avakine (Former), infliximab (Generic), Remicade (Other) Novartis AG Amgen Inc. Samsung Bioepis Co. Ltd. Mylan N.V. Sandoz IQVia Holdings Inc. Coherus BioSciences...
BioCentury | Nov 5, 2019
Company News

Sandoz to launch third Neulasta biosimilar

...sales in 3Q19, with a 31% decline in the U.S. FDA approved Udenyca pegfilgrastim-cbqv from Coherus Biosciences...
...$120 million. Mylan did not break out sales of its biosimilar. Steve Usdin, Washington Editor Sandoz Ltd. Amgen Inc. Coherus BioSciences...
BioCentury | Sep 6, 2019
Regulation

Lackluster U.S. biosimilars market sparks radical recommendations

...in the paper laying out the CSL proposal, he said. Forum members include Boehringer Ingelheim, Coherus BioSciences...
...LLC, Washington, DC BioApprovals, Acton, Mass. Biosimilars Forum, Washington, DC Boehringer Ingelheim GmbH, Ingelheim, Germany Coherus Biosciences...
...Israel U.S. Food and Drug Administration (FDA), Silver Spring, Md. Steve Usdin, Washington Editor Amgen Inc. Boehringer Ingelheim GmbH Coherus BioSciences...
BioCentury | Apr 5, 2019
Company News

Sandoz resubmits BLA for Neulasta biosimilar

...initial BLA in June 2016. Sandoz did not disclose what issues the agency raised (see "Biosimilar Pegfilgrastim...
BioCentury | Feb 5, 2019
Company News

Management tracks: Amazon-Berkshire Hathaway-JPM venture hires Kutan as CTO

...of business development at Denali Therapeutics Inc. (NASDAQ:DNLI), and Robbins was VP of IP at Coherus BioSciences...
BioCentury | Feb 1, 2019
Company News

AbbVie loses $8B in market cap on steeper Humira erosion

...the company is not contemplating any additional deals "of that magnitude." Also on Jan. 25, Coherus BioSciences...
BioCentury | Jan 25, 2019
Company News

AbbVie loses $8B in market cap on steeper Humira erosion

...Inc., the company is not contemplating any additional deals "of that magnitude." Also on Friday, Coherus BioSciences...
BioCentury | Jan 12, 2019
Finance

We all fall down

...Roche (SIX:ROG; OTCQX:RHHBY) China’s National Medical Products Administration approves Hemlibra emicizumab to treat hemophilia A Coherus Biosciences...
Items per page:
1 - 10 of 161